Related Experiment Videos
Systemic lupus erythematosus and pregnancy: a prospective study
A Tincani1, D Faden, M Tarantini
1Clinical Immunology Unit, Brescia General Hospital, Italy.
Clinical and Experimental Rheumatology
|September 1, 1992
Summary
Systemic lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE) patients can achieve successful pregnancies with careful multidisciplinary monitoring. Treatment including aspirin, steroids, and azathioprine resulted in 21 live births with no major complications.
Area of Science:
- Rheumatology
- Obstetrics
- Immunology
Background:
- Systemic lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE) pose risks to pregnancy.
- Managing lupus during pregnancy requires careful consideration of maternal and fetal well-being.
Purpose of the Study:
- To evaluate pregnancy outcomes in patients with SLE and SCLE.
- To assess the safety and efficacy of a flexible treatment regimen during pregnancy.
- To determine the impact of pregnancy on lupus disease activity and relapse rates.
Main Methods:
- Prospective follow-up of 25 pregnancies in 21 patients (20 SLE, 1 SCLE).
- Flexible treatment included low-dose aspirin, medium-low dose steroids, and azathioprine (AZA) after 20 weeks gestation if needed.
- Monitoring of maternal disease activity, obstetrical complications, and fetal outcomes.
Main Results:
- 21 live-born neonates without major treatment-related issues.
- 4 spontaneous first-trimester abortions occurred.
- Maternal lupus relapse rate was 0.07 patient/month, comparable to non-pregnant SLE patients.
- Obstetrical complications were frequent but managed to prevent late fetal loss.
Conclusions:
- Successful pregnancy outcomes are achievable in SLE patients with careful multidisciplinary follow-up.
- The applied flexible treatment regimen appears safe and effective during pregnancy.
- Pregnancy does not necessarily lead to worsening of lupus disease activity.